The feasibility of performing a walking programme in patients with rectal cancer undergoing chemo-radiotherapy (the REx trial)

Not Applicable

Completed

• Conditions: Rectal cancer; Cancer; Malignant neoplasm of rectum

• Registration Number: ISRCTN62859294
• Lead Sponsor: HS Greater Glasgow and Clyde (UK)

Brief Summary

2019 Results article in https://www.ncbi.nlm.nih.gov/pubmed/30657249 feasibility results (added 21/01/2019) 2020 Results article in https://pubmed.ncbi.nlm.nih.gov/32564236/ muscle mass results (added 22/06/2020)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-03-17
• Study Completion: 2016-06-01
• Last Update Posted: 7 November 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

1. Any patient over 18 years of age
2. Independently mobile
3. Has been diagnosed with rectal cancer
4. Planned first line of treatment is chemotherapy and radiotherapy followed by curative surgery
(timing at discretion of surgeon, but expected between 10-12 weeks post-CRX)

Exclusion Criteria

1. Chemotherapy and radiotherapy not first-line treatment
2. Patient has had previous malignancies
3. Significant co-morbidity where inclusion into this trial would put the patient?s health at risk
4. Patient has any mental, physical or psychological impairment that prevents them from giving signed informed consent
5. Patient is already achieving their recommended activity level per week where participation in a walking programme would mean he/she would be exercising at a lower level than normal

Study & Design

• Study Type: Interventional
• Study Design: Not specified